Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 80 for “"KRAS mutation"”.
-
Kras mutation in eutopic endometrium and development of endometriosis : a novel mouse model
… subtype of endometriosis, tend to have a mutation in KRAS codon 12 confined to the epithelium of the endometriosis lesions and within the eutopic endometrium [5]. To achieve a deeper understanding of the roles of the KRAS mutation in the development of endometriosis, this thesis has two …
-
p53 loss and Kras mutation in an invasive murine model of colorectal cancer
… recapitulate the human disease by manipulating mutations that occur during colorectal cancer (CRC) progression. The p53 tumour suppressor gene is commonly mutated in sporadic CRC, though loss alone does not drive intestinal tumorigenesis. When we targeted p53 deletion to the adult murine …
-
Trans-renal tumor DNA as a non-invasive liquid biopsy for KRAS mutation detection in pancreatic cancer
… liquid biopsy for detecting oncogenic KRAS hotspot mutations (G12/G13), which occur in over 90% of PDAC cases. A pilot study of patients with PDAC and other gastrointestinal malignancies was enrolled through the BC Cancer Agency in Vancouver. Paired urine and plasma samples were …
-
INVESTIGATION OF RAS-DEPENDENT GENE EXPRESSION & CELL SURVIVAL SIGNALLING IN COLORECTAL CANCER
KRAS MUTATION OCCURS IN UP TO 60% OF COLORECTAL CANCERS (CRC) AND DEVELOPMENT OF EFFECTIVE TARGETED THERAPIES STILL REMAINS A CHALLENGE. STUDIES HAVE HIGHLIGHTED THE ISSUE OF KRAS DEPENDENCY AND INDEPENDENCY, IMPLYING THAT KRAS MUTATION STATUS IS INADEQUATE AS A BIOMARKER OF TREATMENT RESPONSE. …
-
c-MET and KRAS: Signalling and Clinical Implications in Colorectal Cancer
… cause of death from cancer in North America. The KRAS gene is mutated in approximately 40-50% of all CRC, and this mutation precludes treatment with promising targeted therapeutics. c-MET is a receptor tyrosine kinase that is overexpressed in ~70% of CRCs, and expression is correlated with disease …
-
Targeting PI3-kinase signalling in genetically engineered mouse models of intestinal cancer
… tumour suppressor Apc. Moreover, PI3-Kinase and Kras mutations, which co-occur in human CRC, strongly synergise to drive intestinal tumour initiation and alter the transcriptional landscape. Using these advanced preclinical models as a platform, I have now interrogated the therapeutic impact of …
-
The Impact of Microenvironmental Mediators on the Malignant Progression of Colorectal Cancer
… malignantly, especially in patients with a mutation in the Kirsten rat sarcoma virus (KRAS) gene. Mechanics is an important driver of malignant progression in many cancers, but the understanding of CRC progression in the context of colonic peristalsis (native mechanics of the colon) is …
-
The influence of the EGFR pathway in modulating the efficacy of gemcitabine
… be caused by antagonism between the two drugs or mutations that promote such, possibly RAS mutation. Furthermore, ERK, a critical growth regulator downstream of RAS, may play a role. Therefore the aim of this study is to explore the cytotoxic interaction between gemcitabine and an EGFR inhibitor …
-
Effects of Low-Dose Gamma Radiation in a Murine Model of Benzo[a]pyrene-Induced Lung Cancer
… to investigate the effects of LDR and B[a]P on Kras mutation in tumors, leukocyte cytotoxicity and function, and oxidative stress in mice. Treatment with fractionated doses of LDR (100 mGy) delivered post B[a]P injection suppressed carcinogen-induced lung adenoma formation and prevented the …
-
Signaling crosstalk in cancers
… spectrum of genetic alterations, among which KRAS mutation is the most prominent component with a detection frequency as high as 90%. Hedgehog signaling pathway is involved in developmental process and it’s reactivated in the early stage of carcinogenesis of pancreatic cancer. The coincidence …
-
The emerging role of genetic data in the surgical treatment of patients with colorectal cancer liver metastasis
… in this thesis is largely focused on the role of KRAS and BRAF mutation status in determining prognosis and guiding management among patients with resectable CRLM. The decision to focus our investigation on these two biomarkers reflects both their central importance in colorectal carcinogenesis …
-
Role of ER-phagy and proteostatic defects in pancreatic cancer
… in pancreatic ductal adenocarcinoma (PDAC), Kras mutation in pancreatic acinar cells in mouse models does not lead to immediate morphological changes. Indeed, the molecular events driven by Kras that precede and facilitate the earliest transformation towards malignancy, such as acinar-ductal …
-
The Kras/Mapk Pathway and Ligand Independent Activation of Erα: Implications For The Treatment of Endometrial Cancer
… demonstrated that tumors with an activating KRas mutation are resistant to treatment with letrozole even in combination with everolimus. Tumor growth and cellular proliferation were reduced only after the addition of metformin. To assess signaling through ERα, cells with and without an …
-
Προσδιορισμός των μεταλλάξεων του BRAF γονιδίου στον καρκίνο του παχέος εντέρου
… the predictive and prognosticinfluence of BRAF mutation and other molecular, clinicaland laboratory parameters in stage IV colorectal cancer(CRC). 60 patients were included in this retrospective analysis,and 17 variables were examined for their relation withtreatment response and survival. KRAS …
-
Prognostic role of tumour associated trypsin inhibitor in colorectal cancer patients
… proteins pSTAT3 and pERK1/2, as well as KRAS mutation status. Apart from a significant association between t-TATI expression and KRAS mutation status, there was no intercorrelation between t-TATI or s-TATI and the investigative markers. Expression of pERK1/2 and pSTAT3, and KRAS mutation …
-
Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test
<p>KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is …
-
An in vivo inflammatory loop potentiates KRAS blockade
KRAS inhibitors perform inferior to other targeted drugs. To investigate a possible reason for this, we treated cancer cells with KRAS inhibitors deltarasin (targeting phosphodiesterase-δ), cysmethynil (targeting isoprenylcysteine carboxylmethyltransferase), and AA12 (targeting KRASG12C), and …
-
Ανίχνευση μεταλλάξεων του EGFR και KRAS σε ασθενείς με μη-μικροκυτταρικό καρκίνο του πνεύμονα και διερεύνηση της αξίας τους ως προβλεπτικών παραγόντων ανταπόκρισης στη θεραπεία
… study was to investigate whether the EGFR and KRASmutation status are predictive factors for Greeks patients with NSCLC. Initially, wecalculated the rate and the pattern of EGFR and KRAS mutations in 639 patients withNSCLC and then we correlated the mutations status with …
-
Targeting Ras Neoantigens with Novel Cancer Immunotherapies
… for targeting tumor-specific antigens exist. Mutation-associated neoantigens (MANAs) are peptides derived from intracellular mutant proteins that are presented on the cell surface in peptide-HLA complexes. Targeting MANAs offers a strategy to eliminate cancer cells harboring driver mutations …
Page 1 of 4